These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 14598049)

  • 21. [Use of high dose intravenous immunoglobulin in neurologic disease].
    Korsak J; Zaleska B; Orłowska E; Kotowicz J
    Pol Merkur Lekarski; 2005 Jul; 19(109):98-101. PubMed ID: 16194039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple sclerosis and hepatitis B vaccination: adding the credibility of molecular biology to an unusual level of clinical and epidemiological evidence.
    Comenge Y; Girard M
    Med Hypotheses; 2006; 66(1):84-6. PubMed ID: 16176857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NG2-positive cells in CNS function and the pathological role of antibodies against NG2 in demyelinating diseases.
    Trotter J
    J Neurol Sci; 2005 Jun; 233(1-2):37-42. PubMed ID: 15949494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired early B cell tolerance in patients with rheumatoid arthritis.
    Samuels J; Ng YS; Coupillaud C; Paget D; Meffre E
    J Exp Med; 2005 May; 201(10):1659-67. PubMed ID: 15897279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Auto-reactive B cells in transgenic mice.
    Pasquali JL; Soulas-Sprauel P; Korganow AS; Martin T
    J Autoimmun; 2007 Dec; 29(4):250-6. PubMed ID: 17845841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunological aspects of diseases of the nervous system].
    Vandvik B
    Tidsskr Nor Laegeforen; 1971 Aug; 91(23):1668-71. PubMed ID: 5110440
    [No Abstract]   [Full Text] [Related]  

  • 27. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
    Soelberg Sorensen P
    Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders.
    De Keyser J; Mostert JP; Koch MW
    J Neurol Sci; 2008 Apr; 267(1-2):3-16. PubMed ID: 17935736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues.
    Gold R; Stangel M; Dalakas MC
    Nat Clin Pract Neurol; 2007 Jan; 3(1):36-44. PubMed ID: 17205073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B cells move to centre stage: novel opportunities for autoimmune disease treatment.
    Browning JL
    Nat Rev Drug Discov; 2006 Jul; 5(7):564-76. PubMed ID: 16816838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus.
    Toubi E; Kessel A; Shoenfeld Y
    Hum Immunol; 2005 Apr; 66(4):395-402. PubMed ID: 15866703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating autoimmune demyelination by augmenting lymphocyte apoptosis in the central nervous system.
    Pender MP
    J Neuroimmunol; 2007 Nov; 191(1-2):26-38. PubMed ID: 17931708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B cells as therapeutic targets in autoimmune neurological disorders.
    Dalakas MC
    Nat Clin Pract Neurol; 2008 Oct; 4(10):557-67. PubMed ID: 18813230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there sentinel demyelination before development of primary CNS lymphoma?
    Habek M; Brinar VV; Zarković K; Ozretić D
    J Clin Neurosci; 2008 Sep; 15(9):1069-70; author reply 1071. PubMed ID: 18617406
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic intravenous immunoglobulins.
    Lemieux R; Bazin R; Néron S
    Mol Immunol; 2005 May; 42(7):839-48. PubMed ID: 15829272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination.
    Mikaeloff Y; Caridade G; Assi S; Tardieu M; Suissa S;
    Brain; 2007 Apr; 130(Pt 4):1105-10. PubMed ID: 17276994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of disease: atherosclerosis in autoimmune diseases.
    Sherer Y; Shoenfeld Y
    Nat Clin Pract Rheumatol; 2006 Feb; 2(2):99-106. PubMed ID: 16932663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
    Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED; Travelstead AL; Longee D
    Pediatrics; 2005 Jan; 115(1):e115-9. PubMed ID: 15601813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CNS chemokines, cytokines, and dendritic cells in autoimmune demyelination.
    Segal BM
    J Neurol Sci; 2005 Feb; 228(2):210-4. PubMed ID: 15694210
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.